First patient dosed with Debiopharm’s first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients ...

Independent Data Monitoring Committee (DMC) has approved continuation of trial as planned with no modifications ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of ...

MILAN, Italy I June 16, 2025 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and ...

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer's and other neurodegenerative diseases – ...

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical ...

TEL AVIV, Israel and SHANGHAI, China I June 16, 2025 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) ...

New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis ...

BELTSVILLE, MD, USA and SHANGHAI, China I June 16, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering ...

GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology ...

ROCKVILLE, MD and CAMBRIDGE, MA, USA I June 16, 2025 I Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today ...

INCHEON, South Korea I June 15, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of ...